<![CDATA[Durvalumab Combo Improves Survival in First-Line Extensive-Stage SCLC]]>

Phase 3positivedurvalumabtarlatamabPositive

AI Analysis

Summary

Phase 3 DeLLphi-305 trial demonstrated that durvalumab combined with tarlatamab improved overall survival and progression-free survival in first-line extensive-stage small cell lung cancer (SCLC).

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

improved survival, progression-free survival, and response rates in first-line extensive-stage SCLC

Importance:7/10

Sentiment:

0.80

Phase 3 dataSCLCdurvalumabtarlatamabsurvival improvementDeLLphi-305

Related Companies

$TRAX

Read the original article

Published by Cancer Network on September 9, 2026 2:30 PM

Read Original